Sunovion Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sunovion (US): 1 reconciled FDA prescription therapies, $74.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$74.8M
2024 Medicare Part D Spend$39.6M
2024 Medicaid Spend$35.1M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.